Aldeyra’s attempt at treating dry eye disease has seen a few ups and downs in recent years, but the biotech’s sight to approval got a little clearer Tuesday with a crossover trial success that will pad its case to the FDA this quarter.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,